Registry‐based analysis of Icatibant and C1‐inhibitor use in treatment of laryngeal attacks of hereditary angioedema
- 13 June 2022
- journal article
- letter
- Published by Wiley in Clinical & Experimental Allergy
- Vol. 52 (8) , 994-997
Abstract
No abstract availableThis publication has 9 references indexed in Scilit:
- The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and updateAllergy, 2022
- The Icatibant Outcome Survey: treatment of laryngeal angioedema attacksEuropean Journal of Emergency Medicine, 2016
- Efficacy of Different Medical Therapies for the Treatment of Acute Laryngeal Attacks of Hereditary Angioedema due to C1-esterase Inhibitor DeficiencyThe Journal of Emergency Medicine, 2016
- Repeat treatment of acute hereditary angioedema attacks with open-label icatibant in the FAST-1 trialClinical and Experimental Immunology, 2014
- Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label studyAllergy, 2013
- Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiencyJournal of Allergy and Clinical Immunology, 2012
- Efficacy and safety of recombinant human C1‐inhibitor for the treatment of attacks of hereditary angioedema: European open‐label extension studyClinical & Experimental Allergy, 2012
- Prospective Study of Rapid Relief Provided by C1 Esterase Inhibitor in Emergency Treatment of Acute Laryngeal Attacks in Hereditary AngioedemaJournal of Clinical Immunology, 2010
- Clinical Studies of Sudden Upper Airway Obstruction in Patients With Hereditary Angioedema Due to C1 Esterase Inhibitor DeficiencyArchives of internal medicine (1960), 2003